Dumb Money Live

Today on Dumb Money, how we’re playing the banking crisis. Hint: we bought a bank.

Today on Dumb Money, what we found out about the Tesla robot while researching one of their humanoid robotics competitors.

Alan’s Book: https://amzn.to/3lNrdth Audible: https://amzn.to/3XVABbR Today on Dumb Money, meet Alan Patricof, a wall street legend who has been investing in startups since before "venture capital” was even a thing.

Today on Dumb Money, our best stock pick last year is up 100%. Is it time to sell!?

Today on Dumb Money, the highly anticipated (and briefly leaked) “New Bing” is expected to be made official on February 7. What does it mean for $MSFT and $GOOG stock?

Today on Dumb Money, we’re exploring the best nontraditional investments with Rob Petrozzo, the founder and CEO of Rally. Rally is an online platform that allows people to invest in and trade shares of rare and unique assets such as collectible cars, watches, and other luxury items.

Today on Dumb Money, we’re prepping for the Fed on Wednesday and “triple A” earnings form Apple, Alphabet and Amazon on Thursday. But will reduced consumers cutting back on spending kill the rally we’ve seen so far in 2023?

Today on Dumb Money, the AI revolution has been underway for some time, but the introduction of OpenAI and ChatGPT is taking things to the next level. OpenAI and ChatGPT are two powerful tools that are giving companies the ability to automate processes, create more efficient customer service, and access a wealth of data quickly and accurately. These technologies are already being used by major tech companies such as Microsoft, Oracle, Salesforce, Google, IBM, Intel, AMD and NVIDIA, and they have the potential to revolutionize many industries. Investors should keep an eye on these developments, as there are plenty of opportunities to benefit from OpenAI and ChatGPT technology. So now is the perfect time to learn more and take advantage of this booming industry. Yes, that was all written by AI.

The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we’ll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis. Here are the GLP-1 RA drug makers and their drugs: Eli Lilly (ticker LLY) Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023. Dulaglutide sold as Trulicity. Novo Nordisk (ticker NVO) Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss. Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.

Today’s FTX bankruptcy filing reveals new information and we reveal the real reason we said “no” to SBF and FTX.